vs
Side-by-side financial comparison of Axsome Therapeutics, Inc. (AXSM) and DENNY'S Corp (DENN). Click either name above to swap in a different company.
Axsome Therapeutics, Inc. is the larger business by last-quarter revenue ($191.2M vs $113.2M, roughly 1.7× DENNY'S Corp). On growth, Axsome Therapeutics, Inc. posted the faster year-over-year revenue change (57.4% vs 1.3%). Over the past eight quarters, Axsome Therapeutics, Inc.'s revenue compounded faster (48.1% CAGR vs -0.9%).
Jazz Pharmaceuticals plc is a global biopharmaceutical company with a focus on oncology and neuroscience. It was founded in 2003 in California, United States and is now headquartered in Dublin, Ireland.
Denny's is an American table service diner-style restaurant chain. It operates over 1,400 restaurants in the United States, Canada, México, Puerto Rico, and several other international locations.
AXSM vs DENN — Head-to-Head
Income Statement — Q1 FY2026 vs Q3 FY2025
| Metric | | |
|---|---|---|
| Revenue | $191.2M | $113.2M |
| Net Profit | — | $632.0K |
| Gross Margin | — | — |
| Operating Margin | -33.1% | 9.2% |
| Net Margin | — | 0.6% |
| Revenue YoY | 57.4% | 1.3% |
| Net Profit YoY | — | -90.3% |
| EPS (diluted) | — | $0.01 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $191.2M | — | ||
| Q4 25 | $196.0M | — | ||
| Q3 25 | $171.0M | $113.2M | ||
| Q2 25 | $150.0M | $117.7M | ||
| Q1 25 | $121.5M | $111.6M | ||
| Q4 24 | $118.8M | $114.7M | ||
| Q3 24 | $104.8M | $111.8M | ||
| Q2 24 | $87.2M | $115.9M |
| Q1 26 | — | — | ||
| Q4 25 | $-28.6M | — | ||
| Q3 25 | $-47.2M | $632.0K | ||
| Q2 25 | $-48.0M | $2.5M | ||
| Q1 25 | $-59.4M | $326.0K | ||
| Q4 24 | $-74.9M | $6.8M | ||
| Q3 24 | $-64.6M | $6.5M | ||
| Q2 24 | $-79.3M | $3.6M |
| Q1 26 | -33.1% | — | ||
| Q4 25 | -13.8% | — | ||
| Q3 25 | -27.0% | 9.2% | ||
| Q2 25 | -24.5% | 7.3% | ||
| Q1 25 | -46.9% | 4.7% | ||
| Q4 24 | -61.1% | 12.6% | ||
| Q3 24 | -59.8% | 10.5% | ||
| Q2 24 | -89.5% | 7.9% |
| Q1 26 | — | — | ||
| Q4 25 | -14.6% | — | ||
| Q3 25 | -27.6% | 0.6% | ||
| Q2 25 | -32.0% | 2.1% | ||
| Q1 25 | -48.9% | 0.3% | ||
| Q4 24 | -63.1% | 5.9% | ||
| Q3 24 | -61.7% | 5.8% | ||
| Q2 24 | -91.0% | 3.1% |
| Q1 26 | — | — | ||
| Q4 25 | $-0.55 | — | ||
| Q3 25 | $-0.94 | $0.01 | ||
| Q2 25 | $-0.97 | $0.05 | ||
| Q1 25 | $-1.22 | $0.01 | ||
| Q4 24 | $-1.54 | $0.13 | ||
| Q3 24 | $-1.34 | $0.12 | ||
| Q2 24 | $-1.67 | $0.07 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $305.1M | — |
| Total DebtLower is stronger | $70.0M | — |
| Stockholders' EquityBook value | — | $-32.7M |
| Total Assets | $713.6M | $502.9M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $305.1M | — | ||
| Q4 25 | $322.9M | — | ||
| Q3 25 | $325.3M | — | ||
| Q2 25 | $303.0M | — | ||
| Q1 25 | $300.9M | $1.1M | ||
| Q4 24 | $315.4M | $100.0K | ||
| Q3 24 | $327.3M | $2.9M | ||
| Q2 24 | $315.7M | $2.8M |
| Q1 26 | $70.0M | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | $270.6M | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
| Q1 26 | — | — | ||
| Q4 25 | $88.3M | — | ||
| Q3 25 | $73.7M | $-32.7M | ||
| Q2 25 | $73.1M | $-34.6M | ||
| Q1 25 | $53.2M | $-36.4M | ||
| Q4 24 | $57.0M | $-34.0M | ||
| Q3 24 | $92.9M | $-54.5M | ||
| Q2 24 | $102.9M | $-53.2M |
| Q1 26 | $713.6M | — | ||
| Q4 25 | $689.8M | — | ||
| Q3 25 | $669.3M | $502.9M | ||
| Q2 25 | $639.8M | $491.1M | ||
| Q1 25 | $596.7M | $488.1M | ||
| Q4 24 | $568.5M | $496.3M | ||
| Q3 24 | $561.5M | $461.6M | ||
| Q2 24 | $548.2M | $459.9M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | — | $16.0M |
| Free Cash FlowOCF − Capex | — | $16.0M |
| FCF MarginFCF / Revenue | — | 14.1% |
| Capex IntensityCapex / Revenue | — | 0.0% |
| Cash ConversionOCF / Net Profit | — | 25.28× |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $-18.7M | — | ||
| Q3 25 | $1.0M | $16.0M | ||
| Q2 25 | $-32.4M | $9.4M | ||
| Q1 25 | $-43.4M | $5.0M | ||
| Q4 24 | $-26.2M | $8.5M | ||
| Q3 24 | $-18.6M | $6.6M | ||
| Q2 24 | $-30.1M | $14.2M |
| Q1 26 | — | — | ||
| Q4 25 | $-18.7M | — | ||
| Q3 25 | $988.0K | $16.0M | ||
| Q2 25 | $-32.4M | — | ||
| Q1 25 | $-43.7M | — | ||
| Q4 24 | $-26.2M | — | ||
| Q3 24 | $-18.7M | — | ||
| Q2 24 | $-30.2M | — |
| Q1 26 | — | — | ||
| Q4 25 | -9.6% | — | ||
| Q3 25 | 0.6% | 14.1% | ||
| Q2 25 | -21.6% | — | ||
| Q1 25 | -36.0% | — | ||
| Q4 24 | -22.1% | — | ||
| Q3 24 | -17.9% | — | ||
| Q2 24 | -34.6% | — |
| Q1 26 | — | — | ||
| Q4 25 | 0.0% | — | ||
| Q3 25 | 0.0% | 0.0% | ||
| Q2 25 | 0.0% | — | ||
| Q1 25 | 0.3% | — | ||
| Q4 24 | 0.0% | — | ||
| Q3 24 | 0.1% | 0.0% | ||
| Q2 24 | 0.1% | — |
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | 25.28× | ||
| Q2 25 | — | 3.79× | ||
| Q1 25 | — | 15.38× | ||
| Q4 24 | — | 1.26× | ||
| Q3 24 | — | 1.01× | ||
| Q2 24 | — | 3.97× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
AXSM
| Product sales, net | $189.4M | 99% |
| Royalty revenue and milestone revenue | $1.8M | 1% |
DENN
| Franchisor Owned Outlet | $57.4M | 51% |
| Royalty | $27.7M | 25% |
| Advertising | $18.6M | 16% |
| Occupancy | $7.7M | 7% |
| Initial And Other Fees | $1.7M | 1% |
